TP53 and breast carcinoma: Figure 2e‐i show the effects on cell viability of both Navitoclax and Nav‐Gal at different concentrations in cisplatin‐induced senescent mouse lung adenocarcinoma (KrasG12D/+;p53−/− (KP) L1475(luc) cells) (Turrell et al., 2017), palbociclib‐induced senescent mouse breast cancer 4T1 cells, doxorubicin‐induced senescent human colorectal carcinoma HCT116 cells, irradiation‐induced senescent mouse lung fibroblasts (MLg) and oncogene‐induced senescent human lung fibroblasts (IMR90), versus their nonsenescent counterparts.